高级检索
    王邦琼, 向娟, 王怡, 张先祥, 冯长菊. 维格列汀对2型糖尿病病人胰岛素抵抗指数、超敏C反应蛋白、肿瘤坏死因子-α和白细胞介素-6的影响[J]. 蚌埠医科大学学报, 2019, 44(12): 1653-1655. DOI: 10.13898/j.cnki.issn.1000-2200.2019.12.020
    引用本文: 王邦琼, 向娟, 王怡, 张先祥, 冯长菊. 维格列汀对2型糖尿病病人胰岛素抵抗指数、超敏C反应蛋白、肿瘤坏死因子-α和白细胞介素-6的影响[J]. 蚌埠医科大学学报, 2019, 44(12): 1653-1655. DOI: 10.13898/j.cnki.issn.1000-2200.2019.12.020
    shu
    WANG Bang-qiong, XIANG Juan, WANG Yi, ZHANG Xian-xiang, FENG Chang-ju. Effect of vildagliptin on the levels of HOMA-IR, hs-CRP, TNF-α and IL-6 in patients with type 2 diabetes mellitus[J]. Journal of Bengbu Medical University, 2019, 44(12): 1653-1655. DOI: 10.13898/j.cnki.issn.1000-2200.2019.12.020
    Citation: WANG Bang-qiong, XIANG Juan, WANG Yi, ZHANG Xian-xiang, FENG Chang-ju. Effect of vildagliptin on the levels of HOMA-IR, hs-CRP, TNF-α and IL-6 in patients with type 2 diabetes mellitus[J]. Journal of Bengbu Medical University, 2019, 44(12): 1653-1655. DOI: 10.13898/j.cnki.issn.1000-2200.2019.12.020
    shu

    维格列汀对2型糖尿病病人胰岛素抵抗指数、超敏C反应蛋白、肿瘤坏死因子-α和白细胞介素-6的影响

    Effect of vildagliptin on the levels of HOMA-IR, hs-CRP, TNF-α and IL-6 in patients with type 2 diabetes mellitus

      摘要
    • 摘要:
      目的探索维格列汀对2型糖尿病病人胰岛素抵抗指数（HOMA-IR）、超敏C反应蛋白（hs-CRP）、肿瘤坏死因子-α（TNF-α）和白细胞介素-6（IL-6）的影响。
      方法选取96例2型糖尿病病人，随机分为对照组和观察组，各48例。对照组病人服用盐酸二甲双胍片，观察组病人在对照组二甲双胍基础上给予维格列汀；检测空腹血糖（FBG）、餐后2 h血糖（2hPBG）、糖化血红蛋白（HbA1c）、空腹胰岛素（Fins）、HOMA-IR。
      结果2组治疗前的FBG、2hPBG、HbA1c、Fins、HOMA-IR比较差异均无统计学意义（P>0.05）；治疗后2组各指标均下降，对照组FBG、2hPBG、HbA1c较治疗前降低（P < 0.01），观察组FBG、2hPBG、HbA1c、Fins、HOMR-IR均较治疗前降低（P < 0.01）；且治疗后观察组各项指标均低于对照组（P < 0.01）。2组治疗前hs-CRP、IL-6和TNF-α比较差异均无统计学意义（P>0.05），治疗后对照组IL-6和TNF-α较治疗前明显降低（P < 0.01），观察组hs-CRP、IL-6和TNF-α均较治疗前明显降低（P < 0.01）；且治疗后观察组各项指标均低于对照组（P < 0.01）。
      结论维格列汀能够改善2型糖尿病病人的胰岛素抵抗，同时可显著降低病人的炎症因子水平，具有较高的临床价值。

       

      Abstract:
      ObjectiveTo explore the effects of vildagliptin on the levels of insulin resistance index(HOMA-IR), high sensitive C reactive protein(hs-CRP), tumor necrosis factor alpha(TNF-α) and interleukin -6(IL-6) in patients with type 2 diabetes mellitus.
      MethodsNinety-six patients with type 2 diabetes mellitus were randomly divided into the control group and observation group(48 cases in each group).The control group was treated with metformin hydrochloride tablets, and the observation group was treated with vildagliptin based on the control group.The levels of fasting blood glucose(FBG), 2 h postprandial blood glucose(2hPBG), glycosylated hemoglobin(HbA1c), fasting insulin (Fins) and HOMA-IR were detected in two groups.
      ResultsThe differences of the levels of FBG, 2hPBG, HbA1c, Fins and HOMA-IR between two groups before treatment were not statistically significant(P>0.05).After treatment, these indictors in two groups decreased, the levels of FBG, 2hPBG and HbA1c in control group decreased compared with before treatment(P < 0.01), the levels of FBG, 2hPBG, HbA1c, Fins and HOMR-IR in observation group decreased compared with before treatment, and these indictors in observation group were lower than those in control group(P < 0.01).The differences of the levels of hs-CRP, IL-6and TNF-α between two groups before treatment were not statistically significant(P>0.05).After treatment, the levels of IL-6 and TNF-α in control group significantly decreased compared with before treatment(P < 0.01), the levels of hs-CRP, IL-6 and TNF-α in observation group significantly decreased compared with before treatment, and these indictors in observation group were lower than those in control group(P < 0.01).
      ConclusionsVildaglipti can improve the insulin resistance, and significantly reduce the level of inflammatory factors in type 2 diabetic patients, which has high clinical value.

       

      • HTML全文
      • 参考文献(10)
      • 相关文章
      • 施引文献
    • 资源附件(0)

    /

    返回文章
    返回